Phase 2 N=8 BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
BRAF Mutant Metastatic Melanoma
Primary: Phase 1 - Safety & Recommended Phase 2 Dose (RP2D) — 60 mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=1 Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
Ameloblastoma · BRAF Gene Mutation
Primary: Tumor Response — 0; 0; 0; 0 Participants
Phase 2 N=6 Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease
BRAF V600E Mutation
Primary: Number of Participants With Partial Response to Dabrafenib and Trametinib — 4 Participants
Phase 2 N=9 Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
Recurrent Melanoma · Stage IIIB Melanoma · Stage IIIC Melanoma
Primary: Overall Response Rate in "High Affinity" Group — 0.5 Proportion of participants
N/A N=662 A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
Multiple Myeloma, Neoplasms
Primary: Percentage of Participants With BRAF V600 Mutation Positivity in Tumor Samples by Cancer Type — 0; 3; 11; 0 percentage of participants
Phase 2 N=177 Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
Cancer
Primary: Overall Response Rate (ORR) — 27; 39; 23; 4 Participants
Phase 2 N=51 A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
Neoplasms
Primary: Best Overall Response Rate in TKI-Naive Participants — 42.3 percentage of participants
Phase 2 N=183 A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
BRAF or NRAS Mutant Metastatic Melanoma
Primary: Percentage of Participants With Objective Response (OR) — 4.9; 14.5; 12.0 percentage of participants
Phase 2 N=5 LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Melanoma
Primary: Dose Limiting Toxicity (DLT) [Phase I] — 1 Participants
Phase 2 N=17 LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Stage III Melanoma · Stage IV Melanoma · Unresectable Melanoma
Primary: Change in Kinase Expression — -20.87259; -19.64376; -16.41738; -12.5401 Sum Log 2 Fold Change Kinase Expression
Phase 2 N=208 A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
Multiple Myeloma, Neoplasms
Primary: Confirmed Best Overall Response Rate (BORR) — 37.1; 50.0; 0; 7.4 percentage of participants
Phase 3 N=704 Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Melanoma
Primary: Overall Survival (OS) — 26.0; 17.8 Months
Phase 2 N=92 A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Melanoma
Primary: Number of Participants With a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) as Assessed by the Investigator for Participants Who Had…
Phase 2 N=166 BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Cancer
Primary: Number of Participants With Adverse Events — 3; 4; 36; 50 Participants
Phase 2 N=206 Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Cancer
Primary: Overall Response Rate (ORR) in the Anaplastic Thyroid Cancer (ATC) Cohort — 56; 56; 53; 53 Percentage of Participants
Phase 3 N=322 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
Melanoma
Primary: Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review…
Phase 2 N=7 BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Melanoma
Primary: Number of Participants With Response According to RECIST v1.1 Criteria — 2; 2; 2; 1 Participants
N/A N=274 A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
BRAF V600E Mutation Positive · Metastatic Colorectal Cancer
Primary: Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients — 17; 6; 10; 1 Participants
N/A N=264 Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma
Metastatic Cancers
Primary: Percentage of Participants With V600 BRAF Mutation Status — 41.3; 58.3; 0.4 percentage of participants
Phase 2 N=4 Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 25 percentage of participants
Phase 2 N=28 Selumetinib in Cancers With BRAF Mutations
Adult Solid Neoplasm
Primary: Objective Response Rate in Patients With Cancers Other Than Melanoma — 0 percentage of participants
Phase 2 N=40 A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: Overall Response Rate (ORR), Central Independent Review Assessed by RECIST v1.1 — 75 Percentage (%) of responders
Phase 2 N=6 MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Melanoma
Primary: Number of Participants With Dose Limiting Toxicities (DLT) [Phase I] — 1 Participants
Phase 2 N=97 Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor
Cancer
Primary: Number of Participants With Best Confirmed Response — 0; 1; 0; 13 Participants
N/A N=420 Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Malignant Melanoma
Primary: BRAF Mutation Status According to Cobas 4800 BRAF V600 Mutation Test vs. INCa Laboratories Molecular Genetics Laboratories — 150; 143; 264; 266 number of samples
Phase 2 N=68 A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
Solid Tumors Harboring a BRAF V600 Mutation
Primary: Number of Participants With Dose Limiting Toxicities (DLTs): Phase 1b — 0; 0; 0; 0 Participants
Phase 2 N=17 A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
Advanced BRAF Mutant Cancers
Primary: Dose-limiting Toxicities (DLTs) — 0 DLTs
Phase 2 N=110 MEK162 for Patients With RAS/RAF/MEK Activated Tumors
Solid Tumor and Hematologic Malignancies
Primary: Clinical Benefit Rate (CBR) for Solid Tumors at Week 16 as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 23.1 Percentage of participants
N/A N=716 Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
Melanoma
Primary: Overall Survival (OS) — 16.1; 25.0; 30.0 Months — p=0.02
Phase 1 N=46 A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
Malignant Melanoma
Primary: Area Under the Plasma Concentration-Time Curve (AUC) of RO5185426 From 0 to 8 Hours on Day 1 — 37.54 h*μg/mL